Osaka, Japan, March 14, 2018 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) would like to announce that Shionogi launched XOFLUZATM (generic name: baloxavir marboxil) tablets 10mg/20mg for the treatment of Influenza Types A and B in Japan.

As the cap-dependent endonuclease inhibitor XOFLUZATM suppresses the replication of influenza viruses by a mechanism different from existing anti-flu drugs. XOFLUZATM is an oral tablet that will be dosed only once, offering improved compliances and convenience to the patient. XOFLUZATM was designated for the Sakigake procedure with priority review by the Ministry of Health, Labour, and Welfare of Japan in October 2015. Shionogi was granted approval to manufacture and sell XOFLUZATM on February 23, 2018.

Shionogi’s research and development targets infectious disease as one of its priority areas, and Shionogi have positioned “protecting people from the threat of infectious diseases” as one of its social mission targets. Shionogi strives constantly to bring forth innovative drugs for the treatment of infectious diseases, to protect the health of patients we serve.

‘XOFLUZA™’ Product Description

<table>
<thead>
<tr>
<th>Product Name</th>
<th>XOFLUZATM Tablets 10mg/20mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
<td>Baloxavir Marboxil</td>
</tr>
<tr>
<td>Indications</td>
<td>Influenza Types A and B</td>
</tr>
</tbody>
</table>

Dosage and Administration:

1. The usual dosage for adults and children over 12 years old is two 20 mg tablets (40 mg as baloxavir marboxil) to be administered once. However, patients with a body weight of 80 kg or more should receive four 20 mg tablets (80 mg as baloxavir marboxil) once.
2. For the usual dosage for children younger than 12 years old, the following doses should be administered orally once.

<table>
<thead>
<tr>
<th>Body weight</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>40kg or more</td>
<td>Two 20mg tablets (40 mg as baloxavir marboxil)</td>
</tr>
<tr>
<td>Less than 40 kg and 20 kg or more</td>
<td>One 20mg tablet (20 mg as baloxavir marboxil)</td>
</tr>
<tr>
<td>Less than 20kg and 10kg or more</td>
<td>One 10mg tablet (10 mg as baloxavir marboxil)</td>
</tr>
</tbody>
</table>
Date of manufacturing and marketing approval in Japan: February 23, 2018
Date if listing in the NHI reimbursement price: March 14, 2018
Date of launch: March 14, 2018
NHI price: 1,507.50 yen per XOFLUZATM Tablet 10mg
2,394.50 yen per XOFLUZATM Tablet 20mg
Manufacturer selling company: Shionogi & Co., Ltd.

Supporting information: (past press releases about XOFLUZATM)

Sep/14/2017: S-033188 Phase 3 CAPSTONE-1 Study Results for Treatment of Influenza Presented at the European Scientific Working Group on Influenza Conference
Oct/6/2017: SHIONOGI TO PRESENT S-033188 PHASE 3 CAPSTONE-1 STUDY RESULTS FOR TREATMENT OF INFLUENZA AT IDWEEK 2017
Oct/25/2017: Regarding the Filing for Approval of S-033188 in Japan
Feb/23/2018: XOFLUZATM (Baloxavir Marboxil) Tablets 10mg/20mg Approved for the Treatment of Influenza Types A and B in Japan

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:
Corporate Communications Department
Shionogi & Co., Ltd.
Telephone: +81-6-6209-7885 Fax: +81-6-6229-9596